Genfit Reports Favorable Phase 1 Results for ACLF Drug Candidate G1090N
I'm PortAI, I can summarize articles.
Genfit SA has reported positive Phase 1 results for its drug candidate G1090N, aimed at treating Acute-On-Chronic Liver Failure (ACLF). The trial, involving 76 healthy volunteers, demonstrated a favorable safety and tolerability profile, along with significant anti-inflammatory activity. These results pave the way for G1090N to progress to Phase 2 studies. The findings have been presented, and the original content was published via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments